Washington Research Foundation logo

Washington Research Foundation

wrfseattle.org

Washington Research Foundation supports research and technology commercialization through grants to nonprofit research institutions and investments in early-stage Washington startups, focusing on life sciences and enabling technologies. It aims to advance academic research and help innovations reach the market for public benefit.

Facts

HQ
Seattle, WA, US
Founded
1981
Employees
11
Invests in
We invest in people and partnerships through grantmaking and startup investments. We help to move ideas forward by supporting researchers and entrepreneurs who advance life-changing innovations, and we work closely with the institutions and organizations that underpin this work.

Is this your organization? Claim it

Washington Research Foundation awards $274,849 to WSU’s Jon Oatley to advance Alphatide, a nonhormonal male contraceptive

Washington Research Foundation awarded $274,849 to WSU’s Jon Oatley to advance a nonhormonal, reversible male contraceptive centered on Alphatide, a peptide that blocks ARRDC5–TEX38 interaction to stop sperm maturation without affecting hormones. The grant builds on a prior $100,000 phase 1 award that identified TEX38 as an essential partner of ARRDC5 and supported early development of the peptide lead candidate.

Washington Research Foundation opens May 1 applications for up to 12 three-year postdoctoral fellowships starting 2027

Washington Research Foundation will open applications on May 1, 2026, for up to 12 three-year postdoctoral fellowships starting in 2027 to support early-career scientists at Washington nonprofit research institutions, building on 102 fellowships awarded since 2018 and offering salary, benefits, research expenses, and professional development.

Washington Research Foundation Grants $250,000 to Seattle Children’s Team to Advance PD‑L1–Targeting Bispecific TCE for Fatal Pediatric Diffuse Midline Gliomas

Washington Research Foundation awarded $250,000 to Seattle Children’s researchers Jim Olson and Andrew Mhyre to advance a bispecific T cell engager antibody therapy that targets PD-L1 on diffuse midline gliomas and other lethal brain tumors, converting the tumor’s immune-evasion into a vulnerability; this Phase 2 grant brings WRF’s total support for the project to $350,000 and comes from a larger pledge to SCRI’s Invent postdoctoral program.

People

  • Orin Levine Executive, President & CEO

Online